AU2007265088B2 - Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist - Google Patents

Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist Download PDF

Info

Publication number
AU2007265088B2
AU2007265088B2 AU2007265088A AU2007265088A AU2007265088B2 AU 2007265088 B2 AU2007265088 B2 AU 2007265088B2 AU 2007265088 A AU2007265088 A AU 2007265088A AU 2007265088 A AU2007265088 A AU 2007265088A AU 2007265088 B2 AU2007265088 B2 AU 2007265088B2
Authority
AU
Australia
Prior art keywords
aryl
alkyl
branched
straight chained
galanin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007265088A
Other languages
English (en)
Other versions
AU2007265088A1 (en
Inventor
Thomas P. Blackburn
Roderick E. M. Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dart Neuroscience Cayman Ltd
Original Assignee
Dart Neuroscience Cayman Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dart Neuroscience Cayman Ltd filed Critical Dart Neuroscience Cayman Ltd
Publication of AU2007265088A1 publication Critical patent/AU2007265088A1/en
Assigned to DART NEUROSCIENCE (CAYMAN) LTD reassignment DART NEUROSCIENCE (CAYMAN) LTD Request for Assignment Assignors: HELICON THERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2007265088B2 publication Critical patent/AU2007265088B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
AU2007265088A 2006-06-26 2007-06-26 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist Ceased AU2007265088B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81668206P 2006-06-26 2006-06-26
US60/816,682 2006-06-26
PCT/US2007/072166 WO2008002946A2 (en) 2006-06-26 2007-06-26 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist

Publications (2)

Publication Number Publication Date
AU2007265088A1 AU2007265088A1 (en) 2008-01-03
AU2007265088B2 true AU2007265088B2 (en) 2013-05-23

Family

ID=38738789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007265088A Ceased AU2007265088B2 (en) 2006-06-26 2007-06-26 Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist

Country Status (11)

Country Link
US (1) US20080039496A1 (enExample)
EP (1) EP2032135A2 (enExample)
JP (2) JP2009541493A (enExample)
CN (1) CN101484159A (enExample)
AU (1) AU2007265088B2 (enExample)
BR (1) BRPI0712938A2 (enExample)
CA (1) CA2655829A1 (enExample)
IL (1) IL195903A0 (enExample)
MX (1) MX2008016083A (enExample)
SG (1) SG172735A1 (enExample)
WO (1) WO2008002946A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642281B2 (en) * 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
US20100028839A1 (en) * 2008-07-18 2010-02-04 Tully Timothy P Methods and systems for evaluating memory agents
EP2313098A4 (en) * 2008-07-18 2011-12-21 Dart Neuroscience Llc METHOD AND SYSTEMS FOR THE ASSESSMENT OF MEMORY-PROMOTING ACTIVE SUBSTANCES
AU2012222869B2 (en) * 2011-03-02 2015-08-13 Bionomics Limited Methods of treating a disease or condition of the central nervous system
US8277842B1 (en) 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
CR20160578A (es) * 2014-06-26 2017-02-21 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
CN108349942B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
CA3002489C (en) 2015-11-06 2023-11-07 F.Hoffmann-La Roche Ag Indolin-2-one derivatives
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体
WO2017076842A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092570A1 (en) * 2002-08-07 2004-05-13 Blackburn Thomas P. GAL3 antagonists for the treatment of neuropathic pain
US20040102507A1 (en) * 2001-01-31 2004-05-27 Michael Konkel Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040102507A1 (en) * 2001-01-31 2004-05-27 Michael Konkel Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
US20040092570A1 (en) * 2002-08-07 2004-05-13 Blackburn Thomas P. GAL3 antagonists for the treatment of neuropathic pain

Also Published As

Publication number Publication date
SG172735A1 (en) 2011-07-28
JP2013227357A (ja) 2013-11-07
AU2007265088A1 (en) 2008-01-03
JP2009541493A (ja) 2009-11-26
EP2032135A2 (en) 2009-03-11
BRPI0712938A2 (pt) 2013-03-26
US20080039496A1 (en) 2008-02-14
WO2008002946A3 (en) 2008-05-02
MX2008016083A (es) 2009-03-20
CA2655829A1 (en) 2008-01-03
IL195903A0 (en) 2009-09-01
CN101484159A (zh) 2009-07-15
WO2008002946A2 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
AU2007265088B2 (en) Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
CA2620280C (en) Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
US9616048B2 (en) Anti-depression compounds
KR100558506B1 (ko) 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도
JP2002527419A (ja) Ｇｓｋ−３阻害物質としてのピロール−２，５−ジオン類
CN1639153A (zh) 吲哚基马来酰亚胺衍生物
WO2014172616A2 (en) Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
KR20090069316A (ko) Ｃｂ１ 수용체 조절제로서의 1,5-디페닐-3-피리디닐아미노-1,5-디히드로피롤리딘-2-온
JP2010006813A (ja) うつ病および／又は不安症を治療するためのｇａｌ３受容体アンタゴニストの使用、およびこのような方法において有用な化合物
MX2008011015A (es) Inhibidores de pai-1 para tratamiento de afecciones musculares.
JPH08508743A (ja) Ｃｃｋおよび／またはガストリン拮抗作用を有する１，５−ベンゾジアゼピン誘導体
CN109563054B (zh) 新型芳基乙烯衍生物以及以该新型芳基乙烯为有效成分的药物组合物
AU2005222399A1 (en) Ion channel modulators
WO2025164698A1 (ja) ハンチントン病治療剤及び治療用組成物
JP5336194B2 (ja) 認知機能障害の処置に有用なインドロン化合物
RU2415134C9 (ru) Способ лечения или профилактики физиологических и/или патофизиологических состояний, опосредуемых рецепторами, стимулирующими секрецию гормона роста, триазолы и фармацевтическая композиция на их основе
HK1127736B (en) Indolone compounds useful to treat cognitive impairment

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DART NEUROSCIENCE (CAYMAN) LTD

Free format text: FORMER APPLICANT(S): HELICON THERAPEUTICS, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired